title: Recent advance in lipid management: Focus on PCSK9I (Proprotein Convertase Subtilisin/ Kexin 9 Inhibitors).
abstract: This review discusses recent advances in lipid management, focusing on a new class of drugs known as pcsk9i (proprotein convertase subtilisin/ kexin 9 inhibitors. It describes the basic and clinical pharmacology of these drugs.
authors.affiliation: Department of Endocrinology, Bharti Hospital, Karnal, India.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
mesh_terms: D008078:Cholesterol, LDL; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008055:Lipids; D000091362:PCSK9 Inhibitors; D013381:Subtilisins / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D008055:Lipids; D000091362:PCSK9 Inhibitors; D013381:Subtilisins
keywords: Aliorcumab, Bocicizumab, Evolcumab, LDL cholesterol, Familial hypercholesterolaemia.
  